# National Cancer Institute (NCI)

Organization · id `cardio:org-national-cancer-institute-nci` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=National+Cancer+Institute+%28NCI%29>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class NIH. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: National Cancer Institute (NCI)
- Sponsor class: NIH

## Connected pages

- Sponsors: Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism (`cardio:ct-nct02585713`)
- Sponsors: Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy (`cardio:ct-nct03080883`)
- Sponsors: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (`cardio:ct-nct03206060`)

## Provenance

Content hash: 993c532bce30795e1b6fb3128b321ad0764928eed73eb6e739ef47bb9924ce82
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
